Miyako Satouchi

Miyako Satouchi

Auto-generated profile, based on publicly available information

Miyako Satouchi

Department of Thoracic Oncology Hyogo Cancer Center Akashi Japan

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2010 in Journal of Clinical Oncology
Verified
Journal Article
Open access
NYNobuyuki Yamamoto
Nobuyuki Yamamoto
KNKazuhiko Nakagawa
Kazuhiko Nakagawa
YNYasumasa Nishimura
Yasumasa Nishimura
KTKayoko Tsujino
Kayoko Tsujino
MSMiyako Satouchi
Miyako Satouchi
MFMasahiro Fukuoka
Masahiro Fukuoka
Purpose: This phase III trial of concurrent thoracic radiotherapy (TRT) was conducted to compare third-generation chemotherapy with second-generation chemotherapy in patients with unresectable stage III non–small-cell lung cancer (NSCLC). Patients and Methods: Eligible patients received the following treatments: A (control), four cycles of mitomycin (8 mg/m2 on day 1)/vindesine (3 mg/m2 on days 1, 8)/cisplatin (80 mg/m2 on day 1) plus TRT 60 Gy (treatment break for 1 week); B, weekly irinotecan (20 mg/m2)/carboplatin (area under the plasma concentration-time curve [AUC] 2) for 6 weeks plus TRT 60 Gy, followed by two courses of irinotecan (50 mg/m2 on days1, 8)/carboplatin (AUC 5 on day1); C, weekly paclitaxel (40 mg/m2)/carboplatin (AUC 2) for 6 weeks plus TRT 60 Gy, followed by two courses of paclitaxel (200 mg/m2 on day1)/carboplatin (AUC 5 on day 1). Results: The median survival time and 5-year survival rates were 20.5, 19.8, and 22.0 months and 17.5%, 17.8%, and 19.8% in arms A, B, and C, respectively. Although no significant differences in overall survival were apparent among the treatment arms, noninferiority of the experimental arms was not achieved. The incidences of grade 3 to 4 neutropenia, febrile neutropenia, and gastrointestinal disorder were significantly higher in arm A than in arm B or C (P < .001). Chemotherapy interruptions were more common in arm B than in arm A or C. Conclusion: Arm C was equally efficacious and exhibited a more favorable toxicity profile among three arms. Arm C should be considered a standard regimen in the management of locally advanced unresectable NSCLC.

1 January 2020 in Lung Cancer
Verified
Journal Article
Closed access
KNKazuhiko Nakagawa
Kazuhiko Nakagawa
THToyoaki Hida
Toyoaki Hida
HNHiroshi Nokihara
Hiroshi Nokihara
MMMasahiro Morise
Masahiro Morise
KAKoichi Azuma
Koichi Azuma
TTTomohide Tamura
Tomohide Tamura

1 December 2009
Verified
Journal Article
Closed access
HWHirokazu Watanabe
Hirokazu Watanabe
MOMorihito Okada
Morihito Okada
YKYasushi Kaji
Yasushi Kaji
MSMiyako Satouchi
Miyako Satouchi
YSYozo Sato
Yozo Sato
YAYasuaki Arai
Yasuaki Arai

1 July 2018 in Clinical Lung Cancer
Verified
Journal Article
Open access
THToyoaki Hida
Toyoaki Hida
RKReiko Kaji
Reiko Kaji
MSMiyako Satouchi
Miyako Satouchi
NINorihiko Ikeda
Norihiko Ikeda
AHAtsushi Horiike
Atsushi Horiike
TKToshio Kubo
Toshio Kubo
Atezolizumab, an anti-programmed death-ligand 1 (PD-L1) agent, is effective and well tolerated in patients with pretreated advanced non-small-cell lung cancer (NSCLC). We assessed its efficacy and safety in Japanese patients through subgroup analyses of the phase 3 OAK study (NCT02008227). Key eligibility criteria of this randomized, controlled, open-label, international study include locally advanced/metastatic NSCLC, ≥ 1 prior platinum-based chemotherapy, age ≥ 18 years, measurable disease (Response Evaluation Criteria in Solid Tumors v1.1), and Eastern Cooperative Oncology Group performance status 0 or 1. Atezolizumab 1200 mg or docetaxel 75 mg/m2 was provided intravenously every 3 weeks. Co-primary end points were overall survival (OS) in the intention-to-treat (ITT) population and those with ≥ 1% PD-L1 expression on tumor cells (TC) or tumor-infiltrating immune cells (IC; TC1/2/3 or IC1/2/3). Sixty-four ITT patients were Japanese; 19 had TC1/2/3 or IC1/2/3 status. In Japanese ITT patients, median OS in the atezolizumab arm (n = 36) was longer than the docetaxel arm (n = 28; 21.3 months [95% confidence interval (CI), 11.0-not estimable (NE)] versus 17.0 months [95% CI, 12.5-NE], respectively; hazard ratio 0.80 [95% CI, 0.41-1.57]). In the TC1/2/3 or IC1/2/3 population, median OS was 21.3 months (95% CI, 15.0-NE) and NE in the atezolizumab (n = 11) and docetaxel (n = 8) groups, respectively (hazard ratio, 0.81 [95% CI, 0.22-3.05]). Atezolizumab was generally well tolerated, with no treatment-related deaths. Atezolizumab was effective and well tolerated in pretreated Japanese patients with NSCLC. Results are consistent with the primary analysis of OAK.

1 July 2013 in Lung Cancer
Verified
Journal Article
Closed access
MSMiyako Satouchi
Miyako Satouchi
IOIsamu Okamoto
Isamu Okamoto
HSHiroshi Sakai
Hiroshi Sakai
NYNobuyuki Yamamoto
Nobuyuki Yamamoto
YIYukito Ichinose
Yukito Ichinose
SNShunichi Negoro
Shunichi Negoro

27 March 2007 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MSM Satouchi
M Satouchi
SNS Negoro
S Negoro
YFY Funada
Y Funada
YUY Urata
Y Urata
TST Shimada
T Shimada
TMTetsuya Mitsudomi
Tetsuya Mitsudomi
This study aimed to identify predictive factors associated with prognostic benefits of gefitinib. A total of 221 Japanese patients who received gefitinib (250 mg day−1) were examined retrospectively and potential predictive factors analysed. Overall response rate (ORR) was 24.4% and median survival time (MST) was 8.0 months. In a log-rank test, survival was significantly better in females, patients with adenocarcinoma, never-smokers, favourable performance status (PS) and patients with epidermal growth factor receptor (EGFR) mutation. The lower the smoking exposure (Brinkman Index (BI)=cigarettes per day × years smoked), the better the MST (BI 0: 14.5 months, BI <500: 9.5 months, BI 500 to <1000: 6.9 months, BI 1000: 4.0 months). Positive-EGFR mutation status and PS 0–1 were independent predictors of favourable prognosis by multivariate analysis. Prognosis was significantly different according to EGFR mutation status (with the same smoking status), but not according to smoking status (with the same EGFR mutation status). EGFR mutation status is the most important independent predictor of survival benefit with gefitinib treatment. Although differences in prognosis were observed according to relative smoking status and smoking exposure, the results suggested that smoking is not a direct predictor of prognosis, yet is a surrogate marker of EGFR mutation status.